Cory Renauer

1 week ago | fool.com | Cory Renauer

Pfizer (PFE 0.82%) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management. The stock has been trading about 63% below its all-time high. Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years. At its beaten-down price, the stock offers an eye-popping 7.8% yield.

1 month ago | fool.com | Cory Renauer

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.

1 month ago | fool.com | Cory Renauer

Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have been falling as investors are beginning to assume President Trump will make good on repeated promises to raise the cost of goods entering the U.S. from the country's largest trading partners through tariffs. The biggest trade war losers to date have been the richly valued tech stocks at the top of the S&P 500 (^GSPC 1.08%) index.

1 month ago | fool.com | Cory Renauer

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share. But the good times didn't last. When the market closed on March 11 of this year, the vaccine maker was trading below $34 per share.

1 month ago | fool.com | Cory Renauer

It's been a rough several months for TransMedics Group (TMDX -2.12%) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion devices are the only ones approved by the Food and Drug Administration (FDA) to transport and store multiple solid organs. TransMedics is also the only solid organ transport device maker with a fleet of jets dedicated to transporting donated organs.